Lorlatinib is an ATP-competitive ROS1/ALK inhibitor with potential antitumor activity. Lorlatinib binds to both ALK and ROS1 kinases, resulting in disruption of ALK- and ROS1-mediated signaling and inhibition of ALK- and ROS1-overexpressing tumor cells.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | ALK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye